Kecellitics Biotech Company Ltd

Quick facts

Phase 1 pipeline

• :Anti-CD22-CAR · Oncology
  Chimeric antigen receptor targeting CD22

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kecellitics Biotech Company Ltd portfolio CI brief
• Kecellitics Biotech Company Ltd pipeline updates RSS